Small-molecule dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/β-catenin/TCF/LEF signaling. FH535 inhibits recruitment of the coactivators β-catenin and GRIP1, but not the corepressors NCoR and SMRT. FH535 is selectively toxic to carcinomas expressing the Wnt/β-Catenin pathway, and known to inhibit invasion, migration, and growth in vitro in multiple types of cancer, such as liver cancer and triple negative breast cancer cell lines. The water soluble sodium salt of FH535 is available as Axon 2706.

KEYWORDS: FH535 | supplier | Dual Wnt/β-catenin and PPAR inhibitor | FH-535 | FH 535 | CAS [108409-83-2] | Metabolism | PPARγ | PPARδ | peroxisome proliferator–activated receptor | Nuclear | NR1C | Tcf/Lef